This article is more than 5 years old. Information may no longer be current.

Ophthotech receives $41.7 million in royalty financing from Novo A/S

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Ophthotech Corp. announced in a press release that it received $41.7 million in a second tranche in royalty financing from Novo A/S. This second tranche resulted from Ophthotech reaching an enrollment milestone of a specified number of patients in its multinational phase 3 clinical program of Fovista, an anti-platelet-derived growth factor compound being studied in combination with anti-VEGF therapy for the treatment of neovascular age-related macular degeneration.

As described in a press release, the tranche is the second of three under a $125 million royalty agreement with Novo A/S. The initial funding took place in May 2013.